Skip to main content

Table 1 Clinical and pathological characteristics ofBRCA1mutation carriers (n = 18) and non-carriers (n = 32)

From: High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients

Characteristics BRCA1mutation carriers, n (%) BRCA1mutation non-carriers, n (%) P-value
Age at diagnosis, years    
Median 46 55 0.0648
Range 27-72 28-78  
T stage    
T1 7 (38.89) 6 (18.75) 0.1797
T2 7 (38.89) 15 (46.88) 0.7676
T3 1 (5.56) 9 (28.13) 0.0731
T4 3 (16.67) 2 (6.25) 0.3363
Nodal status    
N0 12 (66.67) 19 (59.38) 0.7637
N1 0 (0.00) 4 (12.50) 0.2828
N2 5 (27.28) 6 (18.75) 0.4944
N3 1 (5.56) 3 (9.38) 0.9999
Metastasis    
M0 17 (94.44) 31 (96.88) 0.9999
M1 1 (5.56) 1 (3.13) 0.9999
Stage    
I 7 (38.89) 5 (15.63) 0.0889
II 5 (27.78) 14 (43.75) 0.3659
III 5 (27.78) 12 (37.50) 0.5482
IV 1 (5.56) 1 (3.13) 0.9999
Histology    
Ductal carcinoma 14 (77.78) 28 (87.50) 0.3984
Tubular carcinoma 0 (0.00) 1 (3.13) 0.9999
Medullary carcinoma 3 (16.67) 0 (0.00) 0.0442
Papillary carcinoma 1 (5.56) 2 (6.25) 0.9999
No data 0 (0.00) 1 (3.13)  
Tumor grade    
Moderately differentiated 3 (16.67) 1 (3.13) 0.1142
Poorly differentiated 12 (66.67) 27 (84.38) 0.1142
No data 3 (16.67) 4 (12.50)  
Ki-67 73 70 0.6494